Revolution Medicines Short Long Term Debt Total Over Time
| RVMD Stock | USD 40.74 1.66 4.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Revolution Medicines Performance and Revolution Medicines Correlation. Revolution |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare Revolution Medicines and related stocks such as Blueprint Medicines Corp, Sana Biotechnology, and Kymera Therapeutics Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPMC | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 9 M | 7.9 M | 4.6 M | 16.3 M | 14.6 M | 95.9 M | 89.6 M | 111.4 M | 562.7 M | 774.1 M | 126.1 M | 166.4 M |
| SANA | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 48.2 M | 71.9 M | 110.9 M | 108.3 M | 104.1 M | 119.7 M | 97.5 M |
| KYMR | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 21.2 M | 18 M | 18 M | 17.3 M | 84.7 M | 97.4 M | 102.2 M |
| GLUE | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 67.8 M | 47 M | 47 M | 46 M | 52.9 M | 44.4 M |
| BDTX | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 8.7 M | 28.5 M | 28.1 M | 25.3 M | 22.8 M | 21.6 M |
| PASG | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 26.3 M | 23.7 M | 21.4 M |
| AKRO | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.5 M | 10.9 M | 26.3 M | 30.3 M | 31.8 M |
| RNA | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 4.9 M | 938 K | 10 M | 10.7 M | 9.9 M | 6.8 M | 8.4 M |
| PTGX | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 6 M | 5.9 M | 3.7 M | 1.1 M | 10.9 M | 5.9 M |
| STOK | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 1.5 M | 2.4 M | 2.1 M | 2.4 M | 1.7 M |
| CCCC | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 13.7 M | 22.9 M | 42.9 M | 87.2 M | 71 M | 81.6 M | 46.2 M |
| AGIO | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 105.2 M | 97.1 M | 85.7 M | 72 M | 57 M | 70.7 M |
| NRIX | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 12 M | 30.6 M | 28.3 M | 32.5 M | 23.1 M |
Revolution Medicines and related stocks such as Blueprint Medicines Corp, Sana Biotechnology, and Kymera Therapeutics Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| Revolution Medicines | RVMD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 38.75
Check out Revolution Medicines Performance and Revolution Medicines Correlation. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Revolution Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.